Why Karyopharm Therapeutics Inc. [KPTI] Stock Still Has Countless Sunny Days Ahead

Karyopharm Therapeutics Inc. [KPTI] shares are down more than -4.67% this year and recently increased 0.01% or $0.17 to settle at $15.70. KPTI has a short ratio of 11.39. This implies that the market is currently less bullish on the outlook for KPTI.

On 7, December 2020, Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting. According to news published on Yahoo Finance, — In a Randomized Investigator Sponsored Study, XPOVIO in Combination with Standard Induction and Consolidation Chemotherapy Demonstrated Improved Survival in Older, Fit Patients with Acute Myeloid Leukemia -.

Analyst Birdseye View:

The most recent analyst activity for Karyopharm Therapeutics Inc. [NASDAQ:KPTI] stock was on March 04, 2020, when it was Initiated with an Overweight rating from Barclays, which also raised its 12-month price target on the stock to $30. Before that, on July 02, 2020, Morgan Stanley Recapitulated an Overweight rating and elevated its amount target to $34. On January 17, 2020, Wedbush Downgrade a Neutral rating. On July 23, 2019, JP Morgan Upgrade an Overweight rating and increased its price target from $8 to $16. On July 05, 2019, Robert W. Baird Reiterated an Outperform rating and increased its price target to $25. On July 05, 2019, H.C. Wainwright Reiterated a Buy rating and boosted its amount target on this stock to $32. On March 01, 2019, JP Morgan Downgrade a Neutral rating and decreased its target amount on this stock from $21 to $7. BofA/Merrill elevated its amount target by recapitulating a higher weight for this stock.

In the past 52 weeks of trading, this stock has oscillated between a low of $13.39 and a peak of $29.61. Right now, according to Wall Street analyst the average 12-month amount target is $31.60. At the most recent market close, shares of Karyopharm Therapeutics Inc. [NASDAQ:KPTI] were valued at $15.70.


Karyopharm Therapeutics Inc. [NASDAQ:KPTI] most recently reported quarterly sales of 21.33 billion, which represented growth of 62.60%. This publicly-traded organization’s revenue is $117,847 per employee, while its income is -$575,187 per employee. This company’s Gross Margin is currently 96.70%, its Pretax Margin is -487.98, and its Net Margin is -488.08. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -62.75, -171.36, -82.24 and -87.03 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 71.47 and the whole liability to whole assets at 42.28. It shows enduring liability to the whole principal at 70.53 and enduring liability to assets at 0.42 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 15.14 points at 1st support level, the second support level is making up to 14.76. But as of 1st resistance point, this stock is sitting at 16.21 and at 16.88 for 2nd resistance point.

Karyopharm Therapeutics Inc. [KPTI] reported its earnings at -$0.73 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.72/share signifying the difference of -0.01 and -1.40% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.63 calling estimates for -$0.58/share with the difference of -0.05 depicting the surprise of -8.60%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Karyopharm Therapeutics Inc. [NASDAQ:KPTI] is 5.40. Likewise, the Quick ratio is also the same, showing Cash ratio at 5.68. Now if looking for a valuation of this stock’s amount to sales ratio it’s 29.04 and it’s amount to book ratio is 25.18.

Insider Stories

The most recent insider trade was by Primiano Christopher Brett, EVP, CBO, GC & Secretary, and it was the sale of 0.14 million shares on Dec 01. Primiano Christopher Brett, the EVP, CBO, GC & Secretary, completed a sale of 772.0 shares on Nov 02. On Oct 30, Lewis Tanya, EVP,Chief Reg.&Quality Officer, completed a sale of 226.0 shares.